Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Atara Biotherapeutics (ATRA) Leases (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Leases readings, the most recent being $6.9 million for Q1 2026.

  • On a quarterly basis, Leases fell 86.46% to $6.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.9 million, a 86.46% decrease, with the full-year FY2025 number at $7.1 million, down 82.25% from a year prior.
  • Leases hit $6.9 million in Q1 2026 for Atara Biotherapeutics, down from $7.1 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $73.6 million in Q2 2022 to a low of $6.9 million in Q1 2026.
  • Median Leases over the past 5 years was $50.8 million (2025), compared with a mean of $43.9 million.
  • Biggest five-year swings in Leases: soared 244.07% in 2023 and later tumbled 86.46% in 2026.
  • Atara Biotherapeutics' Leases stood at $68.0 million in 2022, then dropped by 19.24% to $54.9 million in 2023, then decreased by 27.54% to $39.8 million in 2024, then tumbled by 82.25% to $7.1 million in 2025, then decreased by 2.62% to $6.9 million in 2026.
  • The last three reported values for Leases were $6.9 million (Q1 2026), $7.1 million (Q4 2025), and $10.7 million (Q3 2025) per Business Quant data.